Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 6565-year-old man comes to the clinic for a follow-up visit. He has a history of an unprovoked pulmonary embolism 66 months ago and is on maintenance anticoagulation with rivaroxaban 20 mg20 \text{ mg} daily. Two weeks ago, he was evaluated by a neurologist for new-onset focal impaired awareness seizures and was started on phenytoin. The patient reports no recurrent chest pain, shortness of breath, or bleeding episodes. His vital signs and physical examination are unremarkable. Renal and hepatic function tests are within normal limits. Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

  1. Discontinue rivaroxaban, initiate enoxaparin, and begin warfarin therapyCevap
  2. B
    Continue the current dose of rivaroxaban and monitor anticoagulant efficacy using the prothrombin time (PT)
  3. C
    Discontinue phenytoin, initiate carbamazepine, and maintain the current dose of rivaroxaban
  4. D
    Switch rivaroxaban to dabigatran and continue treatment without routine laboratory monitoring
  5. E
    Maintain the current medication regimen and order a non-contrast computed tomography scan of the head

Cevap

Discontinue rivaroxaban, initiate enoxaparin, and begin warfarin therapy.
The correct answer addresses the severe pharmacokinetic interaction between rivaroxaban and phenytoin. Phenytoin is a potent inducer of both Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Because rivaroxaban is metabolized by CYP3A4 and serves as a substrate for P-gp efflux pumps, coadministration with phenytoin rapidly accelerates its clearance, resulting in subtherapeutic plasma levels and an unacceptable risk of recurrent venous thromboembolism. Direct oral anticoagulants (DOACs) lack widely available, validated assays for routine dose titration. Therefore, the safest clinical approach is to transition the patient to warfarin. Although warfarin metabolism (via CYP2C9) is also induced by phenytoin, its anticoagulant effect can be objectively quantified using the International Normalized Ratio (INR), allowing the clinician to safely titrate the dose upward to achieve the target range of 2.02.0 to 3.03.0. Because the patient has been unprotected for two weeks and warfarin initiation temporarily exacerbates hypercoagulability (due to rapid depletion of Protein C and S), an immediate parenteral bridge with enoxaparin is mandatory until the INR reaches the therapeutic range.

Adım Adım Çözüm

1
Analyze the pharmacokinetic properties of the current medication regimen.
Phenytoin is identified as a strong dual inducer of CYP3A4 and P-glycoprotein (P-gp), while rivaroxaban is a substrate for both.
Identifying drug-drug interactions is critical when a new medication is added to a patient on a direct oral anticoagulant (DOAC).
2
Determine the clinical consequence of the drug-drug interaction.
The induction of CYP3A4 and P-gp significantly increases the clearance of rivaroxaban, leading to subtherapeutic plasma concentrations and a high risk of recurrent pulmonary embolism.
DOAC levels cannot be routinely monitored to titrate around strong inducers, making coadministration contraindicated.
3
Select a safe and monitorable alternative anticoagulant.
Warfarin is chosen because its anticoagulant effect can be directly and objectively monitored using the International Normalized Ratio (INR), allowing for precise dose adjustments despite hepatic enzyme induction.
Objective laboratory monitoring ensures therapeutic anticoagulation when pharmacokinetic variables are altered.
4
Implement a safe transition strategy.
Enoxaparin (a low-molecular-weight heparin) is initiated concurrently with warfarin.
Because the patient's rivaroxaban is currently ineffective, and warfarin causes a transient hypercoagulable state by depleting Protein C and S, a parenteral bridge is required until the INR is therapeutic.

Anahtar Kavram

Patients requiring strong CYP3A4 and P-glycoprotein inducers (e.g., phenytoin, carbamazepine) should not receive DOACs due to unpredictable reductions in anticoagulant efficacy; warfarin with proper bridging and INR monitoring is the standard alternative.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru